Biohit Oyj - Company Announcement

Biohit Oyj’s Chinese joint venture to start production - Gastric cancer risk screening study progressing in China

Biohit Oyj stock exchange release October 24, 2016 at 09:30 am local time (EEST)

Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production
facility has passed official test requirements and has been granted a license
enabling production and sales of products. Biohit HealthCare (Hefei) Co. Ltd
will start manufacturing of the globally unique GastroPanel®-products developed
by Biohit Oyj for the Chinese market, and the first shipments will go to fill
orders relating to the ongoing gastric cancer risk screening study which has
been expanded to cover over 150 hospitals and expected to be concluded by the
end of 2016 on part of the patient screening. The study will continue with
statistical data analysis and reporting from various municipalities and
hospitals that have taken part in the study. The reporting and analysis phase
is expected to be completed during 2017. The results of the analysis will
determine if a population based screening program is feasible. In the meantime
sales of GastroPanel®-tests has continued in the 14 provinces where price
approval has been granted. Biohit Oyj will supply the necessary raw materials
and reagents used in production. 

CEO Semi Korpela, Biohit Oyj: ‘The approval and official permit process have
taken longer than anticipated, but are finally completed. Our joint venture can
now produce GastroPanel®-products for the promising Chinese markets cost
effectively and in large scale. The GastroPanel® (1,2), which is highly
informative and unique in China and elsewhere in the world doesn’t have the
serious medical deficiencies as do the helicobacter tests (e.g. 13C urea breath
test) still in use (3).’ 

CEO Liu Feng, Biohit HealthCare (Hefei) Co. Ltd: ‘We have finalised the
production facility utilising state of the art technology and process
automation for the production, warehousing and logistics of
GastroPanel®-products for the Chinese domestic market. The production capacity
has been tailored to correspond with the capacity needs of a possible
population based screening program.’ 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

1. www.biohithealthcare.com/additional-information

2. www.gastropanel.com/decision-makers/screening-model

3.
http://www.biohithealthcare.com/limitations-of-helicobacter-pylori-diagnostics 



Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com